Study wrapper · #1343
Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.
Editor's note
A useful cross-agent comparison of a side-effect category that gets less attention than nausea and GI complaints, with real numbers behind it. The FAERS data carry the usual caveats: reports are voluntary, lack denominators, and reporting rates are skewed by drug age, media coverage, and formulation differences — so the between-drug percentages rank report proportions, not true incidence. The authors themselves call for prospective studies to pin down actual risk rates. Still, for injection-site reactions specifically, the practical takeaway — common, usually mild, rarely a reason to stop — is well supported.
Plain-language abstract
Researchers reviewed skin-related side effects of injectable GLP-1 drugs, combining published reports with more than 440,000 adverse-event records from the FDA's FAERS database. Skin and injection-site reactions — pain, redness, bruising, itching, and swelling — accounted for about 31% of all reports, the third most common category overall. Rates varied widely by drug: semaglutide sat near the low end at 12.2% of its reports, while tirzepatide was higher at 32.6%. Most reactions were mild to moderate and were managed with supportive care rather than stopping the drug.